Treatment of tumors using specific anti-L1 antibody

US8138313B2 · kind B2 · utility

Assignees

• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE
• Medi&Gene Inc. · DE

Inventors

• Daniela Kelm · Dossenheim, DE
• Peter Altevogt · Trochtelfingen, DE
• Gerhard Moldenhauer · Heidelberg, DE
• Frank Brietling · Heidelberg, DE
• Achim Krüger · Birkenfeld, DE
• Silke Bärreiter · Schriesheim, DE
• Sandra Lüttgau · Weinheim, DE
• Ulrich Mobius · Gauting, DE
• Yi Li · Shanghai, CN

Key dates

• Filing date: Jun 13, 2008
• Grant date: Mar 20, 2012
• Expiry date: Aug 27, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.